Mucosal HIV vaccines: a holy grail or a dud? (Q37736005)

22 August 2017

1 reference

title

Mucosal HIV vaccines: a holy grail or a dud? (English)

1 reference

22 August 2017

0 references

Ali Azizi

1

1 reference

22 August 2017

Haitham Ghunaim

series ordinal

2

1 reference

22 August 2017

Francisco Diaz-Mitoma

series ordinal

3

1 reference

22 August 2017

Jiri Mestecky

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

20 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

4015-4026

1 reference

22 August 2017

24

1 reference

Gastrointestinal disease in simian immunodeficiency virus-infected rhesus macaques is characterized by proinflammatory dysregulation of the interleukin-6-Janus kinase/signal transducer and activator of transcription3 pathway

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The search for effective HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal HIV vaccines: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

Mucosal dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Studying M cells and their role in infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Macrophage HIV-1 infection and the gastrointestinal tract reservoir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Infection of gastrointestinal tract macrophages by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Phylogenetic perspectives in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Dendritic cells and natural killer cells in the pathogenesis of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Adaptive immune response of Vγ2Vδ2 T cells: a new paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Genome-wide innate immune responses in HIV-1-infected macrophages are preserved despite attenuation of the NF-kappa B activation pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Genital-associated lymphoid tissue in female non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Innate and adaptive mucosal immunity in protection against HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal transmission of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Rapid degranulation of NK cells following activation by HIV-specific antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Natural killer cells as an initial defense against pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Natural killer T cells in mucosal homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Unique characteristics of NK cells throughout the human female reproductive tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mutual interference of HIV and natural killer cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

NK cells enhance dendritic cell response against parasite antigens via NKG2D pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Perspectives on mucosal vaccines: is mucosal tolerance a barrier?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal vaccination strategies for women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Polymeric immunoglobulin receptor in intestinal immune defense against the lumen-dwelling protozoan parasite Giardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

IgA and mucosal defense.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A three-tiered view of the role of IgA in mucosal defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal plasma cell repertoire during HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Anti-HIV and -SIV immunity in the vagina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CD8+ T-cells: function and response to HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

T cell immunity to HIV: defining parameters of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The detailed distribution of HLA-A, B, C antigens in normal human organs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Generation of gut-homing T cells and their localization to the small intestinal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Anatomical basis of tolerance and immunity to intestinal antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

NALT- versus Peyer's-patch-mediated mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Immunologic uniqueness of the genital tract: challenge for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Generation of female genital tract antibody responses by local or central (common) mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cell-mediated immunity to HIV in the female reproductive tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A Cocktail of Mycobacterium bovis BCG Recombinants Expressing the SIV Nef, Env, and Gag Antigens Induces Antibody and Cytotoxic Responses in Mice Vaccinated by Different Mucosal Routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Structural requirements for synthetic immunogens to induce measles virus specific CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Intranasal delivery of vaccines against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

Enteric vaccines for the developing world: a challenge for mucosal immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Plasmacytoid dendritic cells mediate oral tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunity and tolerance in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

IL-10 and IL-27 producing dendritic cells capable of enhancing IL-10 production of T cells are induced in oral tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Peyer's patches are required for oral tolerance to proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Induction of IgA B cell differentiation of bone marrow-derived B cells by Peyer's patch autoreactive helper T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Effect of intestinal epithelial cell cytokines on mucosal B-cell IgA secretion: enhancing effect of epithelial-derived IL-6 but not TGF-beta on IgA+ B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Uptake of amplifiable fragments of retrotransposon DNA from the human alimentary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Recent advances in veterinary vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cholera Toxin Promotes the Induction of Regulatory T Cells Specific for Bystander Antigens by Modulating Dendritic Cell Activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Experimental induction of diarrhoea in newly-weaned piglets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Activation and regulation of toll-like receptor 9: CpGs and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CpG-rich islands and the function of DNA methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

Role of chemokine receptors in HIV-1 infection and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.018

7 January 2021

10.1016/J.VACCINE.2010.04.018

Identifiers

DOI

1 reference

22 August 2017

1 reference